Land: Israël
Taal: Engels
Bron: Ministry of Health
METFORMIN HYDROCHLORIDE; PIOGLITAZONE AS HYDROCHLORIDE
TZAMAL BIO-PHARMA LTD
A10BA02
FILM COATED TABLETS
METFORMIN HYDROCHLORIDE 850 MG; PIOGLITAZONE AS HYDROCHLORIDE 15 MG
PER OS
Required
CHEPLAPHARM ARZNEIMITTEL GMBH, GERMANY
METFORMIN
METFORMIN
Competact is indicated as second line treatment of type 2 diabetes mellitus adult patients,particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.
2018-07-31
PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS' REGULATIONS (PREPARATIONS) - 1986 This medicine is dispensed with a doctor’s prescription only COMPETACT 15 MG/850 MG FILM-COATED TABLETS ACTIVE INGREDIENTS AND QUANTITIES: Each tablet contains: pioglitazone (as hydrochloride) 15 mg metformin hydrochloride 850 mg For information about inactive ingredients and allergens in this medicine, see section 2 under 'Important information about some of this medicine’s ingredients', and section 6 'Additional information'. READ THE ENTIRE LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE. This leaflet contains concise information about this medicine. If you have any further questions, consult your doctor or pharmacist. This medicine has been prescribed to treat your illness. Do not pass it on to others. It may harm them, even if it seems to you that their medical condition is similar to yours. USE OF THIS MEDICINE IN CHILDREN AND ADOLESCENTS UNDER 18 YEARS OF AGE IS NOT RECOMMENDED. 1. WHAT IS THIS MEDICINE INTENDED FOR? This medicine is intended for treating type 2 diabetes mellitus (non-insulin dependent) in adults with blood sugar levels that cannot be controlled with metformin treatment alone. Type 2 diabetes usually develops in adulthood particularly as a result of the person being overweight and where the body either does not produce enough insulin (a hormone that controls blood sugar levels), or cannot effectively use the insulin it produces. Your doctor will check whether Competact is working properly 3 to 6 months after you start taking it. Competact helps control the level of sugar in your blood by helping your body make better use of the insulin it produces. THERAPEUTIC GROUP: Pioglitazone: a thiazolidinedione. Metformin: a biguanide. 2. BEFORE USING THIS MEDICINE DO NOT USE THIS MEDICINE IF: • You are sensitive (allergic) to the active ingredients (pioglitazone and metformin) or to any of the other ingredients in this medicine (see section 6). • You have heart failure or have had heart failure in th Lees het volledige document
COMPETACT 15 MG/850 MG Film-coated tablets SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Competact 15 mg/850 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 15 mg of pioglitazone (as hydrochloride) and 850 mg of metformin hydrochloride. Excipient with known effect: Each tablet contains 5 - 3.3 mg of sodium. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet). The tablets are white to off-white, oblong, convex, film-coated, embossed ‘15 / 850’ on one face and ‘4833M’ on the other. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Competact is indicated as second line treatment of type 2 diabetes mellitus adult patients, particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone. After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA 1c ). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained (see section 4.4). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _ _ Posology _Adults with normal renal function (GFR ≥ 90 mL/min) _ The recommended dose of Competact is 30 mg/day pioglitazone plus 1,700 mg/day of metformin hydrochloride (this dose is achievable with one tablet of Competact 15 mg/850 mg, taken twice a day). Dose titration with pioglitazone (added to the optimal dose of metformin) should be considered before the patient is switched to Competact. 2 When clinically appropriate, direct change from metformin monotherapy to Competact may be considered. _Special populations _ _ _ _Elderly _ As metformin is excreted via the kidney, and elderly patients have a tendency to decreased renal function, elderly patients taking Competact should have t Lees het volledige document